Dactinomycin and vincristine toxicity in the treatment of childhood cancer: A retrospective study from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 57, Issue 2, 2011, Pages 252-257

  Langholz, Bryan ^a   Skolnik, Jeffrey M ^b   Barrett, Jeffrey S ^b   Renbarger, Jamie ^c   Seibel, Nita L ^d   Zajicek, Anne ^e   Arndt, Carola A S ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Hepatic toxicity; Neuropathy; Rhabdomyosarcoma; Risk estimation; Wilms tumor

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; TOPOTECAN; VINCRISTINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BODY SIZE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOSENSITIVITY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SAFETY; ETHNICITY; FEMALE; GENDER; HUMAN; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEPHROBLASTOMA; NEUROTOXICITY; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; RACE; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LIKELIHOOD FUNCTIONS; MALE; NEUROTOXICITY SYNDROMES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; RISK FACTORS; VINCRISTINE; WILMS TUMOR;

EID: 79958851632     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22882     Document Type: Article

References (15)

1. Jagt CT, Zuckermann M, Ten Kate F, et al. Veno-occlusive disease as a complication of preoperative chemotherapy for wilms tumor: a clinico-pathological analysis. Pediatr Blood Cancer 2009;53:1211-1215.
2. Moore A, Pinkerton R. Vincristine: can its therapeutic index be enhanced? Pediatr Blood Cancer 2009;53:1180-1187.
3. Arndt C, Hawkins D, Anderson JR, et al. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 2004;22:1894-1901.
4. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-iv: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-3102.
5. Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with wilms' tumor: a report from the national wilms' tumor study group. J Clin Oncol 1998;16:237-245.
6. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for wilms' tumor: a report from the national wilms' tumor study group. J Clin Oncol 1998;16:3744-3751.
7. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972;34:187-220.
8. Aalen OO, Borgan O, Gjessing HK. Survival and event history analysis: a process point of view. New York, NY: Springer; 2008.
9. Veal GJ, Cole M, Errington J, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a united kingdom children's cancer study group study. Clin Cancer Res 2005;11:5893-5899.
10. Mondick JT, Gibiansky L, Gastonguay MR, et al. Population pharmacokinetic investigation of actinomycin-d in children and young adults. J Clin Pharmacol 2008;48:35-42.
11. Frost BM, Lonnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 2003;92:551-557.
12. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999;44:203-209.
13. Lehmann AS, Egbelakin A, Quinney SK, et al. Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients, abstract #9523. Presented at American Society of Clinical Oncology, Chicago, IL; 2010.
14. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by cyp3a5. Drug Metab Dispos 2006;34:1317-1327.
15. Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008;50:769-771.